Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 76321. Отображено 100.
05-01-2012 дата публикации

Novel fructosyl peptide oxidase

Номер: US20120003678A1
Автор: Kazuo Aisaka, Keiko Suzuki, Toshiko Aisaka
Принадлежит: Kyowa Medex Co Ltd

A protein described in any one of [1] to [4] below is provided according to the present invention: [1] a protein comprising the amino acid sequence represented by SEQ ID NO: 1; [2] a protein comprising an amino acid sequence with one or more amino acid deletions, substitutions, or additions in the amino acid sequence represented by SEQ ID NO: 1, and having fructosyl peptide oxidase activity; [3] a protein comprising an amino acid sequence having 80% or higher homology to the amino acid sequence represented by SEQ ID NO: 1, and having fructosyl peptide oxidase activity; and [4] a protein having fructosyl peptide oxidase activity, which is produced by an expression plasmid harbored by the Escherichia coli XL1-Blue MRF' strain deposited under Accession No. FERM BP-11026.

Подробнее
Номер записи: 1
05-01-2012 дата публикации

Gene expression markers of oncolytic virus sensitivity

Номер: US20120004119A1
Автор: Lynda Chin, Marc Lenburg
Принадлежит: Lynda Chin, Marc Lenburg

A method of predicting an efficacy of an oncolytic virus treatment for a tumor comprises calculating a single-gene predictor score for each of a plurality of genes; calculating a predictor score from the sum of the single-gene predictor scores for the plurality of genes; and predicting, if the predictor score is greater than a predictor score threshold, that the treatment would have efficacy, and if the predictor score is less than a predictor score threshold, that the treatment would lack efficacy. Also, methods of predicting an efficacy of a treatment for a tumor comprise identifying the type and subtype of the tumor, wherein the efficacy of the treatment for the type and subtype of the tumor is known.

Подробнее
Номер записи: 2
05-01-2012 дата публикации

Biomarkers for inhibitors with anti-angiogenic activity

Номер: US20120004129A1
Автор: Joyce Behrens
Принадлежит: Merck Patent GmBH

The invention relates to a method for assessing the effect of integrin inhibitors and small molecule ATP site directed multi kinase inhibitors on angiogenesis by the use of certain identified biomarkers. This method is notably beneficial for the determination of the efficacy of integrin inhibitors and small molecule ATP site directed multi-kinase inhibitors mainly used for the treatment of angiogenesis associated diseases such as cancer. Especially, the invention relates to biomarkers linked to angiogenesis that are preferably accessible in body fluids and therefore allow analysis of target modulation in a non-invasive way. The use of said biomarkers for the screening of compounds with integrin-inhibitory activity is also disclosed.

Подробнее
Номер записи: 3
05-01-2012 дата публикации

Animal model for parkinson's disease

Номер: US20120005765A1
Автор: Michael Panneton, Vijaya Kumar, William Burke
Принадлежит: St Louis University

Disclosed are methods and compositions for an animal model of Parkinson's disease. In particular, disclosed is the use of antisense compounds to inhibit the expression of ALDH1A1 in the substantia nigra of an animal brain for the purpose of creating an animal that will displays the symptoms of a human with Parkinson's Disease, including various biochemical, histological, and behavioral characteristics. Also disclosed are methods for using the animal model for Parkinson's disease to test potential therapeutic agents for Parkinson's disease.

Подробнее
Номер записи: 4
12-01-2012 дата публикации

Biomarkers for myocardial ischemia

Номер: US20120009174A1
Автор: Jennifer Van Eyk, QIN Fu, Simon Sheng
Принадлежит: JOHNS HOPKINS UNIVERSITY

This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) Lumican and/or (ii) Extracellular matrix protein 1 and/or (iii) Carboxypeptidase N; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention.

Подробнее
Номер записи: 5
12-01-2012 дата публикации

Differentiating cardiac- and diabetes mellitus-based causes of kidney damage

Номер: US20120009607A1
Автор: Andrea Horsch, Dietmar Zdunek, Georg Hess
Принадлежит: Roche Diagnostics Operations Inc

Disclosed is a method for differentiating in a subject suffering from kidney damage between kidney damage caused by (i) heart failure and/or (ii) diabetes mellitus type 1 or type 2 including the steps of: a) determining the amount of liver-type fatty acid binding protein (L-FABP) and the amount of kidney injury molecule 1 (KIM-1) in a urine-sample of a subject and forming the L-FABP/KIM-1 ratio; b) determining the amount of adiponectin in a urine-sample of said subject; and c) comparing the ratio determined in a) and the amount determined in b) with reference amounts, and establishing the predominant cause of the kidney damage. Also disclosed are a device and a kit for carrying out the method.

Подробнее
Номер записи: 6
12-01-2012 дата публикации

Devices and methods for detecting amniotic fluid in vaginal secretions

Номер: US20120009609A1
Автор: Alexandr Konstantinov, Boris Fuks, Dmitrii D. Petrunin, Evgeny I. Zaraisky, Margarita I. Marshiskaia, Marina N. Boltovskaya, Nelly A. Starosvetskaya, Svetlana V. Nazimova
Принадлежит: N Dia Inc

The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of PAMG-1 in the vagina using anti-PAMG-1 antibodies.

Подробнее
Номер записи: 7
12-01-2012 дата публикации

Novel uses of vegfxxxb

Номер: US20120010138A1
Автор: Andrew Salmon, David Owen Bates, Steven James Harper
Принадлежит: University of Bristol

The invention provides VEGF xxx b, or an agent which selectively promotes the expression of VEGF xxx b in preference to VEGF xxx in cells of a subject or in vitro, or an expression vector system which causes the expression of the VEGF xxx b in a host organism, for use in treating or preventing microvascular hyperpermeability disorders, or in regulating the pro-angiogenic pro-permeability properties of VEGF xxx isoforms, or in supporting epithelial cell survival without increased permeability, or in reducing the nature (for example the number density and/or size) of fenestrations of epithelial filtration membranes in vivo or in vitro.

Подробнее
Номер записи: 8
19-01-2012 дата публикации

Novel diagnostic marker for type 1 diabetes mellitus

Номер: US20120015383A1
Автор: Kyong Soo Park, Sang Gyu Park, Sunghoon Kim
Принадлежит: SEOUL NATIONAL UNIVERSITY HOSPITAL, SNU R&DB FOUNDATION

The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.

Подробнее
Номер записи: 9
26-01-2012 дата публикации

Methods and compositions for liver cancer therapy

Номер: US20120020961A1
Автор: Anne-Sophie Dume, Dominique Joubert, Frédéric HOLLANDE, Leïla Houhou
Принадлежит: Biorealites SAS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Institut National de la Sante et de la Recherche Medicale INSERM

The present disclosure provides methods of treating liver cancer and preventing liver cancer recurrence with anti-progastrin antibodies, methods of monitoring treatment efficacy of anti-progastrin therapy for liver cancer, and compositions useful therefore.

Подробнее
Номер записи: 10
26-01-2012 дата публикации

Diagnostic assays for prostate cancer using psp94 and psa biomarkers

Номер: US20120021925A1
Автор: Douglas Barker, Katrin Atnikov, Stephen Frost, Yilan Zhang
Принадлежит: Miraculins Inc

The application refers to a method for diagnosing prostate cancer through the measurement of the combination of PSP94 (β-microseminoprotein) and F/T PSA biomarkers, the method using urine samples to measure PSP94 and serum samples to analyse F/T PSA. In one embodiment, the PSP94 is standardized to creatinine. Also based on the measurement of PSP94 and F/T PSA are provided methods and kits for (a) diagnosing aggressive prostate cancer; (b) differential diagnosis; and (c) diagnosing the progression of prostate cancer.

Подробнее
Номер записи: 11
26-01-2012 дата публикации

Dosing and monitoring patients on nitrogen-scavenging drugs

Номер: US20120022157A1
Автор: Bruce Scharschmidt
Принадлежит: Ucyclyd Pharma Inc

The invention provides a method for determining a dose and dosing schedule, and making dose adjustments of patients taking PBA prodrugs as nitrogen scavengers to treat nitrogen retention states, including ammonia accumulation disorders as well as chronic renal failure, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered waste nitrogen scavenging drug, and to monitoring patients receiving such drugs.

Подробнее
Номер записи: 12
02-02-2012 дата публикации

Cancer therapy based on tumor associated antigens derived from cyclin d1

Номер: US20120027684A1
Автор: Harpreet Singh, Steffen Walter, Toni Weinschenk
Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.

Подробнее
Номер записи: 13
02-02-2012 дата публикации

Hk1-binding proteins

Номер: US20120027686A1
Автор: Andrew Nixon, Anthony Williams, Daniel J. Sexton, Qi-Long Wu, Robert C. Ladner
Принадлежит: Dyax Corp

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

Подробнее
Номер записи: 14
02-02-2012 дата публикации

Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer

Номер: US20120027799A1
Автор: Cynthia L. Sears, Drew M. Pardoll, Franck Housseau, Shaoguang Wu
Принадлежит: JOHNS HOPKINS UNIVERSITY

The invention provides compositions and methods for useful for the diagnosis of inflammatory bowel disease, ETBF-induced colitis, colonic hyperplasia and/or colon carcinogenesis in a subject in biological samples (e.g., stool, urine, blood, serum, tissue). The invention further provides compositions and methods for the treatment or prevention of colitis, colon cancer, or inflammatory bowel disease (e.g., Crohn's disease).

Подробнее
Номер записи: 15
02-02-2012 дата публикации

Highly sensitive detection method for highly virulent oral cavity bacteria

Номер: US20120028879A1
Автор: Kazuhiko Nakano, Kazuo Umemura, Kazuya Hokamura, Koichiro Wada, Ryota Nomura, Takashi Ooshima
Принадлежит: Hamamatsu University School of Medicine NUC

Provided is a method that involves the detection of protein antigen (PA) and/or collagen-binding protein (CBP) of oral cavity bacteria in a sample, and in which oral cavity bacteria that exacerbate hemolysis are detected for and/or subjects at high-risk for hemolysis aggravation are screened anchor the level of risk of the hemolysis aggravation in a subject is assessed if a PA is not detected anchor a CBP is detected in the sample. Also provided are a detection reagent and kit for use in the method.

Подробнее
Номер записи: 16
02-02-2012 дата публикации

Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids

Номер: US20120029079A1
Автор: Charles R. Wolf, Clifford R. Elcombe
Принадлежит: CXR Biosciences Ltd

The molecules of formula (I) are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of lipis of eicosanoid status or functions may be desirable. Formula (I): Z 1 —Z 1 —Z 2 wherein a) Z 1 represents CO 2 H or a derivative thereof; b) Z 2 represents F, H, —CO 2 H or a derivative thereof; and c) X represents fluorinated alkylene; or a solvate thereof, for example a perfluorinated fatty acid or derivative thereof.

Подробнее
Номер записи: 17
02-02-2012 дата публикации

Methods and compositions comprising tau oligomers

Номер: US20120029169A1
Автор: Eliot J. Davidowitz, James G. Moe
Принадлежит: Oligomerix Inc

Tau protein has a causative role in Alzheimer's disease and multiple other neurodegenerative disorders exhibiting tau histopathology collectively termed tauopathies. The primary function of tau protein is to facilitate assembly and maintenance of microtubules in neuronal axons. In the disease process tau protein becomes modified, loses its affinity to microtubules and accumulates in the cell body where it forms aggregates. The large neurofibrillary tangles formed from tau protein assembled into filaments were thought to be the pathological structure of tau. However, more recent work indicates that smaller, soluble oligomeric forms of tau are best associated with neuron loss and memory impairment. Here, novel compositions of tau oligomers and novel mechanisms for tau oligomer nucleation, extension and termination are taught. Methods for producing and purifying these structures for the development of small molecule and immunotherapeutics as well as antibodies for biomarkers of neurodegenerative diseases are taught.

Подробнее
Номер записи: 18
09-02-2012 дата публикации

Method for assessing inflammatory condition

Номер: US20120034706A1
Автор: Chihiro Miyazawa, Kyoko Miyamoto, Nobuhito Masuda, Yukio Sudo, Yukitaka Ueki
Принадлежит: HAKUJYUJIKAI MEDICAL Inc, Perseus Proteomics Inc

Provided a method for correctly assessing an inflammatory condition of a patient who is receiving a therapy with an IL-6 inhibitor. The method for assessing an inflammatory condition of a patient who is receiving an IL-6 inhibitor, including determining a PTX3 level of a sample derived from a patient who is receiving an IL-6 inhibitor.

Подробнее
Номер записи: 19
09-02-2012 дата публикации

Compositions and methods for the treatment of immune related diseases

Номер: US20120035073A1
Автор: Brisdell Hunte, Hilary Clark, Janet K. Jackman, Jill R. Schoenfeld, P. Mickey Williams, Sarah C. Bodary-Winter, Thomas D. Wu, William I. Wood
Принадлежит: Individual

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Подробнее
Номер записи: 20
09-02-2012 дата публикации

Irak kinase family as novel target and biomarker for alzheimer

Номер: US20120035076A1
Автор: Jeroen Joseph Maria Hoozemans, Maria Helena Hilhorst, Saskia Maria van der Vies
Принадлежит: PAMGENE BV, Vereniging voor Christelijik Hoger Onderwijs Wetenschappelijk Onderzoek en Patientenzorg

The present invention relates to methods and devices for the diagnosis or drug response prediction of neurological disorders by measuring kinase activity and studying the phosphorylation levels and profiles in samples of said patients. Furthermore the present invention relates to methods of identifying drug compounds relevant to neurological disorders by measuring kinase activity and studying phosphorylation levels. Also, the present invention relates to the use of inhibitors of the IRAK protein kinase family or a pharmaceutical composition thereof in the treatment of neurological disorders such as Alzheimer's disease.

Подробнее
Номер записи: 21
16-02-2012 дата публикации

Method and marker for diagnosis of tubular kidney damage and illnesses

Номер: US20120037507A9
Автор: Harald Mischak
Принадлежит: MOSAIGUES DIAGNOSTICS AND THERAPEUTICS AG

A method for the diagnosis of tubular kidney diseases comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide marker being selected from the markers characterized in Table 1 by values for the molecular masses and migration times.

Подробнее
Номер записи: 22
16-02-2012 дата публикации

Methods of classifying the severity of diseases or disorders

Номер: US20120040354A1
Автор: Borge Gronne Nordestgaard, Hans Jorgen Nielsen, Ib Jarle Christensen, Julia Sidenius Johansen, Stig Bojesen
Принадлежит: Herlev Hospital Region Hovedstaden, HVIDOVRE HOSPITAL, RIGSHOSPITALET

The present invention relates to methods of classifying the severity of a non-specific disease or disorder in a subject, wherein a determined level of YKL-40 is compared to one or more reference levels of YKL-40, and the severity of said non-specific disease or disorder is deduced from said comparison. The present invention furthermore relates to a method of classifying the severity of a disease or disorder in a subject, wherein a determined level of YKL-40 is compared to one or more previously determined levels of YKL-40 from the same subject. In both methods, the subject may suffer from a variety of diseases or disorders. In addition the present invention relates to a kit and a device that may be used in the methods of the present invention comprising means for measuring the level of YKL-40 in a sample; and means for comparing the measured level of YKL-40 with one or more reference levels of YKL-40.

Подробнее
Номер записи: 23
16-02-2012 дата публикации

Lung cancer diagnostic polypeptide, method for detecting lung cancer, and method for evaluating therapeutic effect

Номер: US20120040376A1
Автор: Atsuhiko Toyama, Hidewaki Nakagawa, Koji Ueda, Taka-Aki Sato
Принадлежит: RIKEN Institute of Physical and Chemical Research, Shimadzu Corp

A novel biomarker for use in lung cancer diagnosis is provided.

Подробнее
Номер записи: 24
16-02-2012 дата публикации

Biomarkers for stroke

Номер: US20120040858A1
Автор: Byron D. Ford, Gregory Ford
Принадлежит: Morehouse School of Medicine Inc

Biomarkers for stroke and methods for their detection are disclosed. In one aspect, the present application discloses biomarkers for the diagnosis of stroke in a subject. In another aspect, the application discloses a method for the diagnosis of stroke in a subject. The method comprises detection of stroke biomarkers in cerebrospinal fluid, blood, serum or PMBCs of a subject. Also disclosed is a kit for the detection of biomarkers for the diagnosis of stroke in a subject.

Подробнее
Номер записи: 25
23-02-2012 дата публикации

Method for diagnosing endometriosis and diagnostic kit for endometriosis

Номер: US20120045779A1
Автор: Masaharu Ito, Motowo Nabeta, Yasuhito Abe
Принадлежит: Mochida Pharmaceutical Co Ltd

It is an object of the present invention to provide: a method for determining endometriosis, in which a blood sample from a subject can be used, and which is capable of determining endometriosis with higher sensitivity and higher precision than those of a conventional method using only a conventional endometriosis marker such as CA125; and a diagnostic kit for carrying out the method of the present invention. The method for determining endometriosis according to the present invention comprises: a step of analyzing an expression of at least one selected from among an anti-syntaxin autoantibody, an anti-PDIK1L autoantibody and an anti-enolase autoantibody; and a step of determining the presence or absence of the onset of endometriosis based on results of said expression analysis.

Подробнее
Номер записи: 26
01-03-2012 дата публикации

Markers and methods for assessing and treating lupus patients susceptible to photoprovocation

Номер: US20120052066A1
Автор: Cesar Calderon, John Getsy
Принадлежит: Centocor Inc

A method for predicting or detecting susceptibility to lupus of an individual subjected to photoprovocation obtains biological samples from the individual before and after exposure to photoprovocation and compares the levels of at least a portion of members of a 45-member panel or subset thereof to determine whether the individual is susceptible to lupus. The method enables identification of potential lupus patients prior to onset of disease symptoms.

Подробнее
Номер записи: 27
01-03-2012 дата публикации

Compositions, Kits, and Methods for Predicting Anti-Cancer Response to Anthracyclines

Номер: US20120052079A1
Автор: Andrea L. Richardson, Zhigang C. Wang
Принадлежит: Dana Farber Cancer Institute Inc

The present invention is based, in part, on the discovery that amplification of human chromosome 8q22-23 regions and over-expression of 8q22-23 genes (e.g., LAPTM4B and YWHAZ) is associated with and predictive of resistance to anthracycline-type chemotherapy. Accordingly, the invention relates to compositions, kits, and methods for predicting the response of cancer cells, e.g., breast, prostate, lung, ovarian, pancreatic, liver, and colon malignancies to anthracyclines.

Подробнее
Номер записи: 28
01-03-2012 дата публикации

Methods of diagnosing cervical cancer

Номер: US20120052484A1
Автор: Chamorro Somoza Diaz-Sarmiento, Johannes Schweizer, Michael P. Belmares, Peter S. Lu
Принадлежит: Individual

The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.

Подробнее
Номер записи: 29
01-03-2012 дата публикации

Reagent kit for detecting lupus anticoagulant and method of determining presence or absence of lupus anticoagulant

Номер: US20120052585A1
Автор: Kazuyo Yoshida, Masahiro Okuda, Osamu Kumano
Принадлежит: Sysmex Corp

The present invention provides a reagent kit for detecting LA which includes a first clotting time-measuring reagent containing manganese salt and a second clotting time-measuring reagent which contains manganese salt at a concentration lower than that of the first clotting time-measuring reagent or does not contain manganese salt and a method of determining the presence or absence of LA using the kit.

Подробнее
Номер записи: 30
01-03-2012 дата публикации

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Номер: US20120053072A1
Автор: Jeff Gray, Joseph Anderberg, Kevin Nakamura, Paul Mcpherson
Принадлежит: Astute Medical Inc

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble Advanced glycosylation end product-specific receptor, Bactericidal permeability-increasing protein, Interleukin 12, Fibroblast growth factor 23, and Intestinal fatty acid-binding protein as diagnostic and prognostic biomarkers in renal injuries.

Подробнее
Номер записи: 31
01-03-2012 дата публикации

Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy

Номер: US20120053131A1
Автор: Dermot P. McGovern, Jerome I. Rotter, Kent D. Taylor, Stephan R. Targan, Talin Haritunians, Xiuqing Guo
Принадлежит: Cedars Sinai Medical Center

Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis. In another embodiment, the severe form of ulcerative colitis is indicative of MR-UC.

Подробнее
Номер записи: 32
08-03-2012 дата публикации

Use of megalin in urine as marker for detecting renal disorder

Номер: US20120058489A1
Автор: Akihiko Saito, Hiroyuki Kurosawa, Katsuhiko Asanuma, Shinya Ogaswara, Yasuhiko Tomino, Yoshiaki Hirayama
Принадлежит: Denka Seiken Co Ltd, Juntendo Educational Foundation, Niigata University NUC

This invention provides a simple means for detecting a renal disorder, a diagnostic marker for a renal disorder that enables prognostic prediction of a renal disorder (e.g., diabetic nephropathy and IgA nephropathy) and evaluation of the degree of nephropathy at the phase of stage-II diabetic nephropathy by measuring the megalin level in urine associated with a renal disorder used for the detection means, and use of such marker. The invention also provides the use of human megalin obtained from the urine sample of a subject as a marker for detecting a renal disorder.

Подробнее
Номер записи: 33
08-03-2012 дата публикации

Compositions and methods for treating cancer and methods for predicting a response to such treatments

Номер: US20120059021A1
Автор: Andy J. Chien, Rachel TORONI, Randall T. Moon, Rima KULIKAUSKAS, Travis L. Biechele
Принадлежит: UNIVERSITY OF WASHINGTON

The present disclosure relates to the regulation and function of the Wnt/β-catenin signaling pathway and the ERK signaling pathway. The disclosure provides methods of treatment for melanoma by administering both an inhibitor of ERK signaling and an activator of Wnt/β-catenin signaling. These methods may be used alone or in combination with other strategies targeting melanoma cell survival. The disclosure also provides diagnostic methods for predicting a patient's clinical response to inhibitors of ERK signaling.

Подробнее
Номер записи: 34
15-03-2012 дата публикации

Progesterone receptor membrane component 1 (PGRMC1) as an indicator of fertility in animals

Номер: US20120060767A1
Автор: John J. Peluso
Принадлежит: University of Connecticut

Methods of evaluating fertility of an animal based on determination of a PGRMC1 characteristic that correlates with animal fertility. In one embodiment, a sample is obtained from an animal, a PGRMC1 characteristic is determined and compared to a baseline PGRMC1 characteristic, wherein a variation between the determined PGRMC1 characteristic and the baseline characteristic indicates a level of fertility of the animal. A PGRMC1 characteristic can be one or more of PGRMC1 expression, transcription, translation, amino acid sequence, nucleic acid sequence, post-translational modification, cell localization or tissue localization. A sample can be a cell sample, a tissue sample, a blood sample, a lymphocyte sample, an oocyte sample, or a sperm sample. The animal can be male or female. In one embodiment, a variation of PGRMC1 nucleic acid sequence indicates reduced fertility of the animal.

Подробнее
Номер записи: 35
15-03-2012 дата публикации

Novel Target for Regulating Multiple Sclerosis

Номер: US20120064092A1
Автор: Brian A. Zabel, Eugene C. Butcher, Kareem Graham
Принадлежит: Leland Stanford Junior University, US Department of Veterans Affairs VA

Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject.

Подробнее
Номер записи: 36
15-03-2012 дата публикации

Use of Serum Amyloid A Gene in Diagnosis and Treatment of Glaucoma and Identification of Anti-Glaucoma Agents

Номер: US20120064532A1
Автор: Abbot F. Clark, Loretta Graves Mcnatt, Wan-Heng Wang
Принадлежит: NOVARTIS AG

The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.

Подробнее
Номер записи: 37
15-03-2012 дата публикации

Methods for the diagnosis of fetal disease

Номер: US20120065076A1
Автор: David G. Peters, Tianjiao Chu
Принадлежит: University of Pittsburgh

Methods are provided for detecting an aneuploidy in a fetus. These methods can be used to detect trisomy 13, 8 or 21, amongst other aneupoloidies. In some embodiments, the methods include selectively purifying fetal DNA from a maternal biological sample using the methylation status of a CpG containing genomic sequence and genotyping the fetus using the purified fetal DNA, thereby detecting aneuploidy in the fetus.

Подробнее
Номер записи: 38
15-03-2012 дата публикации

Methods and kits for diagnosing osteoarthritis and predicting progression

Номер: US20120065094A1
Автор: Mukundan Attur, Steven B. Abramson
Принадлежит: New York University NYU

This disclosure relates to methods and kits for diagnosing osteoarthritis and for determining the progression of osteoarthritis in a subject.

Подробнее
Номер записи: 39
15-03-2012 дата публикации

Predicting risk of major adverse cardiac events

Номер: US20120065897A1
Автор: Eugene R. Heyman, James V. Snider
Принадлежит: Critical Care Diagnostics Inc

Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.

Подробнее
Номер записи: 40
15-03-2012 дата публикации

Test agent for visceral obesity and use thereof

Номер: US20120066777A1
Автор: Atsunori Kashiwagi, Hiroshi Maegawa, Masatomo Rokushima, Minoru Ikeda, Minoru Suzuki, Shiro Maeda, Tatsuya Takahashi, Tohru Tani, Yoshihiro Kawamura
Принадлежит: RIKEN Institute of Physical and Chemical Research, Shiga University of Medical Science NUC, Shionogi and Co Ltd

Disclosed are: a method for detecting (diagnosing) visceral obesity in a subject; a test agent useful for the method; a method for searching for a substance that can be used as an active ingredient for ameliorating visceral obesity; and an ameliorating agent for visceral obesity or a medicinal agent for preventing a metabolic disease developed as a result of the progression of visceral obesity. As the test agent, a polynucleotide which comprises at least 15 nucleotides and can hybridize with a nucleotide sequence for coiled-coil domain containing protein 3 (CCDC3) gene or a nucleotide sequence complementary to the nucleotide sequence under stringent conditions or an antibody capable of recognizing CCDC3 protein is used.

Подробнее
Номер записи: 41
22-03-2012 дата публикации

Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine

Номер: US20120070432A1
Автор: Jeffrey Scott Wiezorek, Jennifer Joy Kordich, Jonathan David Graves
Принадлежит: AMGEN INC

Methods and compositions for treatment of exocrine pancreatic cancer in a human patient comprising administering a therapeutically effective amount of a DR5 agonist and gemcitabine. Methods and compositions for treating a patient by identifying the alleleic variant of FcγRIIIA.

Подробнее
Номер записи: 42
22-03-2012 дата публикации

Methods

Номер: US20120071337A1
Автор: Andreas Christian GÜNTERT, Darragh P.W. O'Brien, Helen Louise Byers, James Campbell, Simon Harold Lovestone
Принадлежит: Electrophoretics Ltd, KINGS COLLEGE LONDON

The invention provides a method for aiding the diagnosis or prognostic monitoring of Alzheimer's disease in a subject, said method comprising; providing a sample of blood obtained from said patient; assaying the amount of gelsolin present in said sample; comparing the amount of gelsolin present in said sample to a reference amount of gelsolin present in a sample from a healthy subject, wherein detection of a gelsolin level in the sample from said patient which is lower than the gelsolin level in the reference sample indicates an increased likelihood of Alzheimer's disease in said patient. Other markers are C1 protease inhibitor and ceruloplasmin. Both blood samples and tissue samples have been investigated.

Подробнее
Номер записи: 43
22-03-2012 дата публикации

Therapeutic application of isolated naturally-occuring soluble truncated forms of IL-23 receptor

Номер: US20120071422A1
Автор: Grant Gallagher, Jonathan Brazaitis, Raymond Yu
Принадлежит: Medical Diagnostic Laboratories LLC

The present invention relates to an isolated naturally-occurring soluble truncated IL-23Rα protein, which is a translated protein resulting from a mRNA splice variant of IL-23Rα. The soluble IL-23Rα proteins (e.g., Δ9 and Δ8,9) represents a novel soluble IL-23Rα protein, which is lacking a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end (due to frame-shift). ELISA reveals that Δ9 is present in blood and can serve as a diagnostic tool for auto-immune diseases including Crohn's disease. There is also provided a method of recombinant production for this soluble truncated form of IL-23Rα protein. More importantly, the present invention provides an utility application of the Δ9 and Δ8,9 protein in inhibit IL-23R-mediated cell signaling. More particularly, Δ9 and Δ8,9 blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of Δ9 and Δ8,9 in treating a human patient inflicted with Crohn's disease.

Подробнее
Номер записи: 44
29-03-2012 дата публикации

Method for Detecting and Quantitating Multiple-Subcellular Components

Номер: US20120075453A1
Автор: Michael Kilpatrick, Triantafyllos Tafas
Принадлежит: Ikonisys Inc

A method for detecting and quantitating multiple and unique fluorescent signals from a cell sample is provided. The method combines immunohistochemistry and a fluorescent-labeled in situ hybridization techniques. The method is useful for identifying specific subcellular components of cells such as chromosomes and proteins.

Подробнее
Номер записи: 45
29-03-2012 дата публикации

Modulation of autophagy and and serotonin for treatment of multiple myeloma related diseases

Номер: US20120076770A1
Автор: Alessandra Romano, Amy Van Meter, Antonella Chiechi, Emanuel Petricoin, Lance Liotta, Virginia Espina
Принадлежит: Individual

THE INVENTION RELATES TO compounds, proteins and methods of treatment therewith. Aspects of embodiments of the invention further relates to compounds and methods of treatment for bone, bone marrow, and bone tissue.

Подробнее
Номер записи: 46
29-03-2012 дата публикации

Methods of enhancing drug delivery and effectiveness of therapeutic agents

Номер: US20120076862A1
Автор: Neil P. Desai, Patrick Soon-Shiong
Принадлежит: Individual

The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by co-administering a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane with the therapeutic agent. The present invention in another aspect provides a method of treatment or a method of selecting patients for treatment of a disease (such as cancer) with the combination of a therapeutic agent and a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane based on one or more characteristics of the target tissue that correlates or indicates the capability of getting enhanced therapeutic agent uptake as a result of the co-administration of the taxane nanoparticle composition in the target tissue (referred to as “the drug uptake capability”). Also provided are pharmaceutical compositions, article of manufacture, and kits useful for methods described herein.

Подробнее
Номер записи: 47
29-03-2012 дата публикации

Diagnosis of multiple sclerosis

Номер: US20120077686A1
Автор: Francisco J. Quintana, Howard L. Weiner, Irun R. Cohen
Принадлежит: Brigham and Womens Hospital Inc

The present invention relates to methods and kits for diagnosing multiple sclerosis (MS) in a subject. Particularly, the present invention relates to methods and kits for diagnosing a subtype of MS in a subject, the subtype selected from relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and a pathologic sub-type of MS lesions selected from Pattern I and Pattern II MS lesion.

Подробнее
Номер записи: 48
29-03-2012 дата публикации

Compartment-Specific Non-HLA Targets for Diagnosis and Prediction of Graft Outcome

Номер: US20120077689A1
Автор: Atul J. Butte, Minnie M. Sarwal
Принадлежит: Leland Stanford Junior University

Methods and composition are provided for diagnosing or predicting the status or the outcome of a graft transplant. In some embodiments, the presence or absence of one or more proteins recognizing a non-HLA/non ABO antigen is determined. The obtained result is then employed to diagnose or predict the status or outcome of the graft transplant. Also provided are compositions, systems and kits that find use in practicing the subject methods.

Подробнее
Номер записи: 49
05-04-2012 дата публикации

Glioblastoma Biomarkers, and Methods and Compositions

Номер: US20120083422A1
Автор: Claudius Mueller, Emanuel Petricoin, Lance Liotta, Virginia Espina
Принадлежит: Individual

Glioblastoma multiforme biomarkers, methods, and compositions are provided. Methods of selecting a treatment for a patient with a brain neoplasm, including Glioblastoma multiforme, are provided. Methods of treating a patient at risk for Glioblastoma multiforme are provided.

Подробнее
Номер записи: 50
05-04-2012 дата публикации

Biomarkers, Methods and Kits for the Diagnosis of Rheumatoid Arthritis

Номер: US20120083423A1
Автор: Isabelle Auger, Jean Roudier
Принадлежит: Universite de la Mediterranee Aix Marseille II

The present invention relates to peptides biomarkers that are specifically recognized by autoantibodies present in the sera of patients with Rheumatoid Arthritis (RA). More specifically, the invention provides epitopes of PAD4, of BRAF, and of calpastatin as well as methods and kits for using these sequences for the diagnosis of RA, in particular for the diagnosis of RA in CCP-negative subjects.

Подробнее
Номер записи: 51
12-04-2012 дата публикации

Therapeutics for age-related macular degeneration

Номер: US20120087928A1
Автор: Kameran Lashkari
Принадлежит: Individual

The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD.

Подробнее
Номер записи: 52
12-04-2012 дата публикации

Methods of diagnosing insulin resistance and sensitivity

Номер: US20120088245A1
Автор: Anny Xiang, Jerome I. Rotter, Kent D. Taylor, Leslie Raffel, Mark O. Goodarzi, Thomas A. Buchanan, Xiuqing Guo, Yii-Der I. Chen
Принадлежит: Cedars Sinai Medical Center

Methods of diagnosing susceptibility to metabolic insulin resistance and other related conditions are disclosed. The method provides means of diagnosing susceptibility to insulin resistance in Hispanic Americans by determining the presence of a risk haplotype at the LPL locus, the LPIN1 locus, and/or elevated levels of gamma-glutamyl transferase.

Подробнее
Номер записи: 53
19-04-2012 дата публикации

Ipp complex as marker for erlotinib treatment

Номер: US20120095029A1
Автор: Angelique Augustin, Barbara Klughammer, Guillemette Duchateau-Nguyen, Hanno Langen, Helene Meistermann, Jens Lamerz, Laurent Essioux, Manuel Tzouros, Sabrina Golling, Stefan Scheiblich
Принадлежит: Hoffmann La Roche Inc

The present invention provides biomarkers which are predictive for the clinical benefit of erlotinib hydrochloride treatment in cancer patients.

Подробнее
Номер записи: 54
26-04-2012 дата публикации

Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof

Номер: US20120101029A1
Автор: Asya Varshavsky, Boaz Kigel, Gera Neufeld, Ofra Kessler
Принадлежит: Rappaport Family Institute for Research in the Medical Sciences

A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.

Подробнее
Номер записи: 55
26-04-2012 дата публикации

Method for screening inhibitor for inhibiting interaction between beta-amyloid peptide and vegf and inhibitor searched by the same

Номер: US20120101284A1
Автор: Chan-Won Park, In-Cheol Kang
Принадлежит: Innopharmascreen Inc

There is provided a compound found by screening a material for inhibiting a binding between a beta-amyloid 1-42 peptide and VEGF165, in which the inhibition material screened according to the present invention can improve effectiveness as a material for treating Alzheimer's disease.

Подробнее
Номер записи: 56
03-05-2012 дата публикации

Methods of administering pif agonist peptides and uses thereof

Номер: US20120107318A9
Автор: Eytan R. Barnea
Принадлежит: BioIncept LLC

A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a T H 2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection. Further, polyclonal antibodies against PIF peptides were generated that serve for precise measurements of PIF in biological fluids. They document pregnancy presence and viability as well it helps for monitoring pregnancies at risk in humans as well as in farm and non farm animals, improving animal husbandry, where currently no specific pregnancy test exists. Also the PIF antibodies may have additional therapeutic properties for treatment of HIV, and malaria.

Подробнее
Номер записи: 57
03-05-2012 дата публикации

Method for predicting weight gain associated with a pharmaceutical therapy

Номер: US20120108947A1
Автор: Jennifer Kay Leohr
Принадлежит: Eli Lilly and Co

Methods for using TRL V6 as a biomarker for the risk of weight gain associated with treatment of a patient with a pharmaceutical agent, as for example, olanzapine.

Подробнее
Номер записи: 58
10-05-2012 дата публикации

Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity

Номер: US20120115127A1
Автор: Marc K. Hellerstein
Принадлежит: UNIVERSITY OF CALIFORNIA

The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis. Molecular flux rates within the one or more biochemical processes serve as biomarkers and are quantitated and compared with the molecular flux rates (i.e., biomarker) from control subjects (i.e., subjects not exposed to the compounds). Any change in the biomarker in the subject relative to the biomarker in the control subject provides information to evaluate therapeutic efficacy of an administered drug or a toxic effect and to develop the compound further if desired. In one aspect of the invention, stable isotope-labeled substrate molecules are administered to a subject and the label is incorporated into targeted molecules in a manner that reveals molecular flux rates through metabolic pathways of interest.

Подробнее
Номер записи: 59
10-05-2012 дата публикации

Hydroxycholesterol immunoassay

Номер: US20120115169A1
Автор: James J. Donegan, Jeffrey Kroll Adams, Michael C. Mullenix, Robert Elliot Zipkin, Wayne Forrest Patton
Принадлежит: Enzo Life Sciences Inc

Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.

Подробнее
Номер записи: 60
17-05-2012 дата публикации

Superoxide dismutase variants and methods of use thereof

Номер: US20120121568A1
Автор: Danica Chen, Xiaolei Qiu
Принадлежит: UNIVERSITY OF CALIFORNIA

The present disclosure provides variant superoxide dismutase polypeptides, compositions comprising the polypeptides, and nucleic acids comprising nucleotide sequences encoding the polypeptides. The present disclosure provides methods of reducing oxidative damage in a cell, tissue, or organ. The present disclosure provides methods of identifying agents that increase superoxide dismutase activity.

Подробнее
Номер записи: 61
17-05-2012 дата публикации

Test for Predicting Neutralization of Asparaginase Activity

Номер: US20120121570A1
Автор: Yann Godfrin
Принадлежит: Individual

Method of in vitro measurement of the presence of factors that are able to neutralize asparaginase activity in a sample of blood, plasma, serum or derived medium that may contain asparaginase neutralizing factors, obtained from a patient, comprising mixing of said sample with asparaginase, incubation of said mixture, then measurement of the residual asparaginase activity in the mixture and determination or quantification of the presence of said neutralizing factors. Method for predicting the efficacy of a treatment with asparaginase.

Подробнее
Номер записи: 62
17-05-2012 дата публикации

Treatment of oncostatin m receptor beta mediated heart failure

Номер: US20120121579A1
Автор: Henning Warnecke, Jochen Pöling, Thomas Braun, Thomas Kubin, Wolfgang Rees
Принадлежит: Max Planck Gesellschaft zur Foerderung der Wissenschaften eV

The present invention relates to an inhibitor of the oncostatin M receptor β or an inhibitor of an activator of the oncostatin M receptor β for use in the treatment and/or prevention of heart failure. The present invention also relates to a method of treating and/or preventing heart failure comprising administering a pharmaceutically effective amount of an inhibitor of the oncostatin M receptor β or an inhibitor of an activator of the oncostatin M receptor β to a subject in need thereof. Further, the present invention also relates to methods of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of heart failure.

Подробнее
Номер записи: 63
17-05-2012 дата публикации

Agents and Methods Related to Reducing Resistance to Apoptosis-Inducing Death Receptor Agonists

Номер: US20120122724A1
Автор: Robert P. Kimberly, TONG Zhou
Принадлежит: UAB RESEARCH FOUNDATION

Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins.

Подробнее
Номер записи: 64
17-05-2012 дата публикации

Markers for endometrial cancer

Номер: US20120122726A1
Автор: Andreas Döll, Antonio Gil Moreno, Cristina Perez, Elisabet Rossell, Jaume REVENTÓS PUIGJANER, Miguel Abal Posada, Tamara Maes
Принадлежит: Geadic Biotec AIE

The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.

Подробнее
Номер записи: 65
17-05-2012 дата публикации

Diagnostic agent for ischemic heart disease risk group

Номер: US20120122777A1
Автор: Issei Komuro, Kenji Hashimoto, Masao Daimon, Tohru Minamino
Принадлежит: Daiichi Pure Chemicals Co Ltd

The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor.

Подробнее
Номер записи: 66
17-05-2012 дата публикации

Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies

Номер: US20120123695A1
Автор: Bart Burington, David Dornan
Принадлежит: Genentech Inc

The invention provides methods and kits useful for predicting or assessing responsiveness of a patient having B-cell lymphoma to treatment with anti-CD40 antibodies.

Подробнее
Номер записи: 67
24-05-2012 дата публикации

Diagnosis of restenosis in patients undergoing percutaneous coronary intervention

Номер: US20120128660A1
Автор: Kailash Prasad
Принадлежит: UNIVERSITY OF SASKATCHEWAN

The present invention relates to compounds, compositions, methods and/or kits for determining and/or predicting and/or diagnosing and/or treating restenosis in a patient.

Подробнее
Номер записи: 68
24-05-2012 дата публикации

Diagnosis and treatment of autoimmune demyelinating diseases

Номер: US20120128698A1
Автор: Menno Van Lookeren Campagne
Принадлежит: F Hoffmann La Roche AG

The present invention concerns the diagnosis and treatment of autoimmune demyelinating diseases, such as multiple sclerosis (MS), by means of a CLM-I agonist.

Подробнее
Номер записи: 69
24-05-2012 дата публикации

Scn5a splicing factors and splice variants for use in diagnostic and prognostic methods

Номер: US20120129179A1
Автор: Samuel Dudley
Принадлежит: University of Illinois

Provided herein are methods of identifying a subject at risk for arrhythmias, heart failure or sudden cardiac death. In exemplary aspects, the method comprises the step of determining a level of splicing factor hLuc7a, splicing factor RBM25 and/or PERK in a biological sample obtained from the subject, wherein an increased level, compared to a control level, indicates a risk for arrhythmia or heart failure. The invention also provides methods of diagnosing hypertrophic cardiomyopathy (HCM), or a risk therefor, in a subject. The method comprises the step of determining a level of E28D, RBM25, PRPF40A, or LUC7L3, or a combination thereof, in a biological sample obtained from the subject, wherein an increased level is indicative of the subject having HCM or a risk therefor. Diagnostic kits comprising binding agents for the markers are furthermore provided.

Подробнее
Номер записи: 70
24-05-2012 дата публикации

Methods and compositions for diagnosing ankylosing spondylitis using biomarkers

Номер: US20120129185A1
Автор: Robert L. Wong, Walter P. Maksymowych
Принадлежит: Abbott Biotech Ltd Bermuda

The invention provides a method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker.

Подробнее
Номер записи: 71
24-05-2012 дата публикации

Inhibition of ApoE Cleavage Activity in the Treatment of ApoE-Related Disorders

Номер: US20120129782A1
Автор: Karl H. Weisgraber, Mei Xiu Steele, QIN Xu, Robert W. Mahley, Stephen Barry Freedman, Yadong Huang
Принадлежит: J David Gladstone Institutes

The present invention provides methods for treating apoE-related disorders. The methods generally involve administering an effective amount of an agent that inhibits activity of an enzyme that cleaves apoE.

Подробнее
Номер записи: 72
24-05-2012 дата публикации

Detection and treatment of autoimmune disorders

Номер: US20120130350A1
Автор: Anne M. Stevens, Neelufar Mozaffarian
Принадлежит: Seattle Childrens Hospital

Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand.

Подробнее
Номер записи: 73
31-05-2012 дата публикации

Means and methods for diagnosing thyroid disorders

Номер: US20120132797A1
Автор: Alexandre Prokoudine, Bennard Van Ravenzwaay, Edgar Leibold, Eric Fabian, Georgia Coelho Palermo Cunha, Hennicke Kamp, Jan C. Weimer, Michael Manfred Herold, Ralf Looser, Tilmann B. Walk, Volker Strauss, Werner Mellert
Принадлежит: BASF SE

The present invention relates to a method for diagnosing thyroid disorders. It also relates to a method of determining whether a compound is capable of inducing a thyroid disorder in a subject and to a method of identifying a drug for treating a thyroid disorder. Furthermore, the present invention relates a device for diagnosing a thyroid disorder and diagnostic uses.

Подробнее
Номер записи: 74
31-05-2012 дата публикации

Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells

Номер: US20120134969A1
Автор: Hideki Ando, Hiroshi Handa, Kentaro Hotta, Takumi Itoh
Принадлежит: Tokyo Institute of Technology NUC

With an aim to provide a novel factor inducing proliferation of neural stem cells and differentiation of these cells into nerve cells, a pharmaceutical composition comprising 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed, a method including administering the pharmaceutical composition to a non-human animal and inducing proliferation of neural stem cells or neural progenitor cells of the non-human animal and differentiation of these cells into nerve cells, and a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex, using CRBN, are provided.

Подробнее
Номер записи: 75
31-05-2012 дата публикации

Materials and methods for measuring nitric oxide levels in biological fluids

Номер: US20120136054A1
Автор: Daniel J. Gibson, Gregory S. Schultz
Принадлежит: University of Florida Research Foundation Inc

The subject invention presides novel devices and methods for the measurement of nitric oxide in biological samples, including wound fluid samples. These advantageous devices and methods can be used for clinicians to monitor the wound's nitric oxide metabolism and/or response to treatment.

Подробнее
Номер записи: 76
31-05-2012 дата публикации

Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis

Номер: US20120136057A1
Автор: Dayan Goodenowe, M. Amin Khan, Pearson W.K. Ahiahonu, Shawn Ritchie
Принадлежит: Phenomenome Discoveries Inc

A compound of formula (I): wherein R represents a hydroxy substituted C 24 -C 40 straight chain aliphatic group containing at least one double bond in the carbon chain; and at least one carbon in the chain is substituted with a hydroxy group. Such compounds are useful for detecting inflammation, inflammatory disorders and cancer in a subject, and can also be used in therapeutic applications including treatment and/or prevention of these conditions. Pharmaceutical compositions, combinations and supplements, as well as methods of treatment using the described compounds are therefore also described.

Подробнее
Номер записи: 77
07-06-2012 дата публикации

Use of pkc isozymes for diagnosis and treatment of neuroblastoma

Номер: US20120141498A1
Автор: Mildred E. Acevedo-Duncan, Rekha S. Patel
Принадлежит: UNIVERSITY OF SOUTH FLORIDA, US Department of Veterans Affairs VA

The present invention pertains to the use of PKC-epsilon (PKC-ε), PKC-delta (PKC-δ), PKC-eta, and/or PKC-theta as biomarker(s) for prediction and/or detection of neuroblastoma, as well as therapeutic targets for treatment of neuroblastoma.

Подробнее
Номер записи: 78
07-06-2012 дата публикации

Treatment of non-proliferative cystic disease

Номер: US20120141506A1
Автор: David L. KLEINBERG
Принадлежит: New York University NYU

The present invention relates generally to the treatment of non-proliferative cystic disease of the breast. More particularly, the present invention relates generally to the treatment of non-proliferative cystic disease of the breast in BRCA1 mutant carriers. Accordingly, the invention relates to the use and application of compounds or agents, including somatostatin analogs, that inhibit insulin-like growth factor I (IGF-I) or insulin-like growth factor I receptor signaling for the treatment of non-proliferative cystic disease of the breast. The invention further relates to the use and application of these compounds or agents for the treatment of non-proliferative cystic disease of the breast in BRCA1 patients. The invention also relates to use of somatostatin analog SOM230 in treatment of non-proliferative cystic disease of the breast and more particularly, to use of somatostatin analog SOM230 in treatment of BRCA1 associated non-proliferative cystic disease.

Подробнее
Номер записи: 79
07-06-2012 дата публикации

Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States

Номер: US20120142781A1
Автор: Ibert Clifton Wells
Принадлежит: Magnesium Diagnostics Inc

This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.

Подробнее
Номер записи: 80
14-06-2012 дата публикации

Antibodies That Bind Amyloid Oligomers

Номер: US20120148591A1
Автор: Rakez Kayed
Принадлежит: University of Texas System

Embodiments of the invention are directed to compositions and methods related to immunogenic compositions comprising the amino acid sequence of SEQ ID NO:1 and amyloid oligomer specific antibodies that specifically bind an oligomer comprising such a peptide.

Подробнее
Номер записи: 81
14-06-2012 дата публикации

Methods of evaluating cells and cell cultures

Номер: US20120149013A1
Автор: Stephen J. Duguay, Stephen M. Rapko
Принадлежит: Genzyme Corp

Methods of evaluating the composition of a cell culture (e.g., to distinguish chondrocytes from fibroblasts) and methods for evaluating the phenotype of an individual cell (e.g., as a chondrocyte) are disclosed. The methods may be used, for example, for assessing chondrocyte cultures used for treatment of cartilage defects. In some embodiments, the invention involves identifying cell culture composition or the identity of a cell based on expression level of a fibroblast marker. In other embodiments, the invention involves comparing expression levels of at least one chondrocyte marker and at least one fibroblast marker in a cell culture sample or in an individual cell. In illustrative embodiments, the chondrocyte marker is hyaluronan and proteoglycan link protein 1 (HAPLN1), and the fibroblast marker is microfibrillar associated protein 5 (MFAP5).

Подробнее
Номер записи: 82
14-06-2012 дата публикации

Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein b ratios

Номер: US20120149596A1
Автор: Joseph L. Witztum, Sotirios Tsimikas
Принадлежит: UNIVERSITY OF CALIFORNIA

The present invention relates to the analysis of oxidized phospholipids (OxPL) on apolipoprotein B-100 in patients at high risk or with documented coronary artery disease (CAD) or acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction or suspected of being at risk for ACS. Such methods are useful for diagnostic purposes and for monitoring the effects of dietary interventions or with drugs such as statins. More particularly, the present invention relates to methods for determining OxPL/apoB ratios as indices of atherosclerosis regression and plaque stability.

Подробнее
Номер записи: 83
21-06-2012 дата публикации

Method and Pharmaceutical Composition for Use in the Treatment of Neurodegenerative Disorders

Номер: US20120156221A1
Автор: Alain Van Dorsselaer, Jose Alain Sahel, Ludivine Perrocheau, Thierry Leveillard
Принадлежит: Institut National de la Sante et de la Recherche Medicale INSERM

The invention relates to compounds which activate the BASIGIN signaling pathway, preferably agonists of BASIGIN, for the treatment of neurodegenerative disorders.

Подробнее
Номер записи: 84
28-06-2012 дата публикации

Test method on renal diseases

Номер: US20120164662A1
Автор: Akihiko Saito, Hiroyuki Kurosawa, Katsuhiko Asanuma, Masanori Hara, Shinya Ogasawara, Yasuhiko Tomino, Yoshiaki Hirayama
Принадлежит: Denka Seiken Co Ltd, Juntendo Educational Foundation, Niigata University NUC

Provided is a test method for the assessment of the necessity of renal biopsy in a subject to be tested, who is suspected of having a renal disease. Specifically provided are a test method for a renal disease, including using urinary podocalyxin and one or more additional markers in combination, and a test reagent for use in the test method and a test reagent kit for use in the test method. The present invention allows the discrimination of a poor prognosis group even for poor prognosis cases with no overt findings in a conventional test method, and thus allows the assessment of a renal disease, the assessment of the necessity of renal biopsy, prognostic prediction, and the like to be performed exactly.

Подробнее
Номер записи: 85
28-06-2012 дата публикации

Spinal muscular atrophy (sma) treatment via targeting of smn2 splice site inhibitory sequences

Номер: US20120165394A1
Автор: Elliot J. Androphy, Natalia N. Singh, Nirmal K. Singh, Ravindra N. Singh
Принадлежит: University of Massachusetts UMass

The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the SMN2 ISS-N1 site in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The ISS-N1 blocking agents of the invention cause elevated expression of SMN protein, thus compensating for the loss of SMN protein expression commonly observed in subjects with spinal muscular atrophy (SMA).

Подробнее
Номер записи: 86
05-07-2012 дата публикации

Use of pkc-zeta as a breast cancer tumorigenic biomarker as well as a target for treatment of breast cancer

Номер: US20120171219A1
Автор: Diondra D. Hill, Mildred Acevedo-Duncan
Принадлежит: UNIVERSITY OF SOUTH FLORIDA, US Department of Veterans Affairs VA

The present invention provides use of protein kinase C-zeta (PKC-ζ) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer.

Подробнее
Номер записи: 87
05-07-2012 дата публикации

Further use of protein kinase n beta

Номер: US20120171220A1
Автор: Anke Klippel-Giese, Jörg Kaufmann
Принадлежит: SILENCE THERAPEUTICS AG

The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.

Подробнее
Номер записи: 88
05-07-2012 дата публикации

S. aureus allergen

Номер: US20120171238A1
Автор: Alexander M. Hirschi, Angelika Stöcklinger, Birgit Linhart, Elli Greisenegger, Josef Thalhamer, Kavita Reginald, Kerstin Westritschnig, Rudolf Valenta, Tamara Kopp, Thomas Werfel
Принадлежит: BIOMAY AG

The invention discloses the use of a protein with an amino acid sequence according to SEQ. ID. NO. 1 or a naturally occurring fragment or variant thereof for identifying infections with S. aureus in a human sample. More specifically, IgE molecules specific for SEQ. ID. NO. 1 are detected in the sample of the patient. Many atopic dermatitis patients have IgE specific for SEQ. ID. NO. 1.

Подробнее
Номер записи: 89
05-07-2012 дата публикации

Combination of spla2 activity and oxpl/apob cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event

Номер: US20120171705A1
Автор: Alain Tedgui, Joseph Witztum, Sotirios Tsimikas, Ziad Mallat
Принадлежит: Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Diderot Paris 7, UNIVERSITY OF CALIFORNIA

The use of a combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event or for the monitoring of a cardiovascular disease.

Подробнее
Номер записи: 90
05-07-2012 дата публикации

Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

Номер: US20120172244A1
Автор: Amanda Hummon, Steven Buechler
Принадлежит: University of Notre Dame

Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed.

Подробнее
Номер записи: 91
05-07-2012 дата публикации

Therapeutic use for alpha1 proteinase inhibitor in hematopoiesis

Номер: US20120172286A1
Автор: Cynthia L. Bristow
Принадлежит: INSTITUTE FOR HUMAN GENETICS AND BIOCHEMISTRY

A previously unrecognized fundamental property of α 1 PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified α 1 PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with HW-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of α 1 PI with its receptors, HLE CS and LRP, influences the level of cells of different lineages. Genetic and proteolytic modification of α 1 PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.

Подробнее
Номер записи: 92
05-07-2012 дата публикации

Process for the identification of compounds for treating cancer

Номер: US20120172581A1
Автор: Damià TORMO CARULLA, María Soledad Soengas González
Принадлежит: Centro Nacional de Investigaciones Oncologicas CNIO

Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.

Подробнее
Номер записи: 93
12-07-2012 дата публикации

Methods of optimizing disease treatment

Номер: US20120177632A1
Автор: Makoto Inoue, Mari L. Shinohara
Принадлежит: Duke University

Provided are methods for optimizing treatment of an autoimmune disease in a subject, methods for identifying and/or selecting a compound as a therapeutic for an autoimmune disease, methods of identifying a patient that is responsive to IFN-β therapy, and methods for identifying an agent that inhibits NLRP 3 inflammasome activity.

Подробнее
Номер записи: 94
12-07-2012 дата публикации

Antibodies That Specifically Bind to A Beta Oligomers and Use Thereof

Номер: US20120177664A1
Автор: Makoto Umeda, Naofumi Takamatsu, Shinobu Fujii, Tatsuki Yokoseki, Toshiyuki Ito, Yasuhide Okamoto, Yukiho Imai
Принадлежит: Immunas Pharma Inc

The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.

Подробнее
Номер записи: 95
12-07-2012 дата публикации

Biomarkers and methods for detecting alzheimer's disease

Номер: US20120178637A1
Автор: David Witte, Jeffrey F. Waring, Melanie Joy Patterson, Viswanath Devanarayan
Принадлежит: ABBOTT LABORATORIES

Methods for classifying a test sample as indicative of Alzheimer's disease use protein and peptide biomarkers that are differentially expressed in the cerebral spinal fluid (CSF) of subjects with Alzheimer's disease relative to age-matched controls. The methods also use protein and peptide signatures indicative of Alzheimer's disease. Microarrays and kits for detecting the protein and peptide biomarkers in CSF samples can be used to classify Alzheimer's disease state from test samples.

Подробнее
Номер записи: 96
19-07-2012 дата публикации

Treating neurological disorders

Номер: US20120183542A1
Автор: John Lincecum, Kyungmin Hahm, Linda C. Burkly, Steve Perrin, Timothy Zheng
Принадлежит: BIOGEN IDEC MA INC

Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented.

Подробнее
Номер записи: 97
19-07-2012 дата публикации

Method Of Calculating A Phosphorus-Protein Ratio

Номер: US20120184036A1
Автор: Amanda K. Stennett, Frank A. Gotch, Norma J. Ofsthun
Принадлежит: Individual

A method of identifying a patient who is non-compliant with prescribed diet and/or phosphate binder regimen calculates a phosphorus-protein ratio (PPR) by calculating the patient's protein intake, measuring the patient's serum phosphorus concentration, and estimating the amount of phosphorus removed by the patient's kidneys from measured residual urea clearance. The PPR is the ratio between the total amount of phosphorus removed from the patient and the patient's protein intake. The method enables identifying a patient that is non-compliant with prescribed diet and/or phosphate binder regimen if the PPR is outside of an acceptable range.

Подробнее
Номер записи: 98
19-07-2012 дата публикации

Methods for treating inflammation

Номер: US20120184616A9
Автор: Dakai Liu, Elazar Rabbani, James J. Donegan, Richard Jin, Riddhi Bhattacharyya, Wei Cheng, Xiaofeng Li, Yazhou Zhang
Принадлежит: Individual

The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.

Подробнее
Номер записи: 99
26-07-2012 дата публикации

Modular Extracorporeal Systems and Methods for Treating Blood-Borne Diseases

Номер: US20120189711A1
Автор: David G. Greenberg, Juan N. Walterspiel, Scott Puritz, Tatiana Koutchma
Принадлежит: Somerset Group Enterprises Inc

Extracorporeal systems and methods for treating blood-borne diseases in a subject or for developing drugs to treat blood-borne diseases include various environmental and treatment modules that can be tailored to a specific disease or infection. In certain embodiments of the systems and methods, a blood sample is treated with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, sonification, radiation, or a combination thereof, under environmental conditions that are effective for the treatment.

Подробнее
Номер записи: 100